This interaction may result in a reduced activity of the ceramide synthase pathway and, finally, reduced cellular ceramide concentration, which might possibly explain the reduced adverse effects of diazepam on COVID-19 compared to other BZRAs. This evidence concerns the gene TLCD3B and COVID-19.